Specific topics include a survey of immunology, superantigens, antigen presenting cells, cell mediated immune defense, cytokines as molecular mediators, interleukens, interferons as viral inhibitors and immune response mediators, interferon signaling through Janus kinases and signal transducers and activators of transcription, flow cytometry, immunoassays, genetic engineering of antibody molecules, autoantibodies and autoimmunity, synovial mast cells in inflammatory arthritis and the molecular and cell biology of HIV/AIDS.
Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to Intracellular Receptors (IRs) and Signal Transducers and Activators of Transcription (STATs).
Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to Intracellular Receptors (IRs) and Signal Transducers and Activators of Transcription (STATs).
Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to Intracellular Receptors (IRs) and Signal Transducers and Activators of Transcription (STATs).
founded in 1987, is a leader in gene transcription technology, particularly intracellular receptor (IR) technology and Signal Transducers and Activators of Transcription (STATs).
Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to Intracellular Receptors (IRs) and Signal Transducers and Activators of Transcription (STATs).
founded in 1987, is a leader in gene transcription technology, particularly intracellular receptor (IR) technology, and Signal Transducers and Activators of Transcription (STATs), Ligand applies IR and STATs technology to the discovery and development of small molecule drugs to enhance therapeutic and safety profiles and to address major unmet patient needs in cancer, women's health and skin diseases, as well as osteoporosis, cardiovascular and inflammatory disease.
Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to Intracellular Receptors (IRs) and Signal Transducers and Activators of Transcription (STATs).
